Obermatt
See Similar Stocks →

Arcturus Therapeutics Holdings

NMQ:ARCT · US03969T1097
BiotechnologySmall

360

26
Profit price50
Owner Earnings Yield1
Dividend Yield1
Price/Sales56
Price/Book52
Return on Capital77
Cash Return on Capital70
Return on Equity79
EBIT Margin10
Gross Profitability51
Accruals47
Owner Earnings Margin70
Sales growth10
Profit growth52
Reinvestment95
Price momentum11
Debt load56
Refinancing12
Debt Payback1
Liquidity5
Analyst ratings24
Opinion Changes20
Price Target Upside72
Market mood61
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Arcturus Therapeutics Holdings doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Employees149
Websitearcturusrx.com
ISINUS03969T1097
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsInfectious DiseasesRespiratoryHepatologyVaccinesHealth DiagnosticsGenetic DisorderBiotechnologyHealth CareScience and Engineering

Description

Arcturus Therapeutics Holdings Inc. (Arcturus) operates as a global messenger RNA medicines company. The company focuses on the development of liver and respiratory rare disease therapeutics. The company has ongoing Phase 2 clinical studies for its R…

Analysis

Middle-of-the-road

Arcturus Therapeutics Holdings Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is stretched. The company scores 0/20 on our value-creation score: not creating value. Analysts lean positive.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
22
2026

All-time high

57

Mar 2026

All-time low

22

Jun 2026

Average rank

40

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
56
—
—
—
Price/Earnings
34
—
—
—
Price/Book
52
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
41
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Arcturus Therapeutics Holdings with its peers
Moderna
NSQ:MRNA
20
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Sutro Biopharma
NMQ:STRO
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Savara
NSQ:SVRA
71
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Intellia Therapeutics
NMQ:NTLA
25
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Stoke Therapeutics
NSQ:STOK
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tharimmune
NAQ:THAR
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →